Lab
Spector Scientific Lab INC.
Spector Scientific Lab INC. was paid $1.62M by Medicaid between Sep 2018 and Dec 2024, across 34 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 47% of everything it billed.
33Billing provider infoSPECTOR SCIENTIFIC LAB INC.
DEERFIELD BEACH, FL 33442
DEERFIELD BEACH, FL 33442
33aNPI1215390422assigned 04/04/2016
33bProvider typeClinical Medical Laboratory
28Total paid$1.62M
24GClaims31,523
24DCodes billed34
24AFirst – last monthSep 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#32 of 225
Median peer was paid$74K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30 | $3K | |
| 2019 | 25 | $584.62 | |
| 2020 | 2,236 | $121K | |
| 2021 | 9,401 | $332K | |
| 2022 | 11,917 | $475K | |
| 2023 | 4,430 | $266K | |
| 2024incomplete | 3,484 | $423K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 47% | 12,279 | 8,653 | $759K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 18% | 2,842 | 1,739 | $287K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 14% | 2,496 | 1,195 | $225K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 6.5% | 8,000 | 5,637 | $105K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.3% | 1,124 | 694 | $70K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.7% | 1,594 | 889 | $44K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.3% | 963 | 509 | $38K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 991 | 393 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 337 | 165 | $10K |
| 81226 | <1% | 23 | 22 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 153 | 144 | $6K |
| 81306 | <1% | 23 | 22 | $5K |
22 more codes
| 81225 | <1% | 20 | $4K | |
| 81406 | <1% | 20 | $4K | |
| 81350 | <1% | 20 | $4K | |
| 81231 | <1% | 23 | $3K | |
| 81227 | <1% | 23 | $3K | |
| 81328 | <1% | 23 | $3K | |
| 81335 | <1% | 23 | $3K | |
| 81232 | <1% | 23 | $3K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 74 | $3K |
| 81381 | <1% | 20 | $3K | |
| 81401 | <1% | 20 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 83 | $2K |
| 81355 | <1% | 23 | $2K | |
| 81283 | <1% | 23 | $1K | |
| 81241 | <1% | 22 | $1K | |
| 81240 | <1% | 23 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 68 | $97.18 |
| 80061 | Lipid panel | <1% | 26 | $39.14 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38 | $14.37 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 23 | $6.26 |
| 81374 | 0% | 20 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDZEVA, ANNA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Analyze Pathology INC. | Deerfield Beach, FL | $7.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.